Arca
Skip to content
Tools
Tools

mRNA

Nucleic acid in Hepatitis B virus that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Other 1

Approved0

    Phase 31

    • Bepirovirsen

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        BepirovirsenPhase 3GSKOligonucleotideAntisense inhibitormRNA antisense inhibitor7

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 7 in all, from ClinicalTrials.gov.
        B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study ParticipantsBepirovirsenPhase 4Not yet recruitingGlaxoSmithKlineNov 2, 2026
        A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult ParticipantsBepirovirsenPhase 1Not yet recruitingGlaxoSmithKlineOct 29, 2026
        Bepirovirsen Liver Biopsy StudyBepirovirsenPhase 2Not yet recruitingNational University Health System, SingaporeJul 10, 2026
        A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney DiseaseBepirovirsenPhase 1Active, not recruitingGlaxoSmithKlineSep 11, 2025
        A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)BepirovirsenPhase 2Active, not recruitingGlaxoSmithKlineAug 5, 2024
        Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)BepirovirsenPhase 2Active, not recruitingGlaxoSmithKlineJul 11, 2024
        Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)BepirovirsenPhase 2Active, not recruitingGlaxoSmithKlineJul 8, 2021

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4662967, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.